Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study.

摘要: Background: Previous studies have shown that the taxane, docetaxel, is effective in treating gastric cancer. The aim of this study was to assess efficacy and safety docetaxel combination with 5-fluorouracil (5-FU) leucovorin (LV). Methods: Thirty patients histologically proven locally advanced and/or metastatic cancer WHO performance status 0–2 were enrolled received either 75 or 100 mg/m2 as a 1-h intravenous infusion on day 1 every 28 days. All also 5-FU (1800 mg/m2) plus LV (500 mg/m2), by continuous over 24 h days 1, 8, 15 Chemotherapy given for at least two cycles. Results: Of 25 evaluable patients, 3 showed complete response, 4 partial 11 had stable disease. overall response rate 28.0% (95% confidence interval [CI], 10.4, 45.6). median time progression 5.9 months CI, 5.4, 6.5), survival 7.7 7.2, 8.3) intent-to-treat population. most frequent grade III IV hematological toxicities neutropenia anemia. Febrile observed 10% 2.4% prophylactic use granulocyte colony-stimulating factor (G-CSF) reduced incidence severity neutropenia. Other rare. Conclusion: Docetaxel weekly advanced/metastatic This new docetaxel-containing shows promise third-generation treatment option